A novel therapeutic target for Alzheimer's disease offers new hope for millions of patients worldwide.
A research team led by Dr. Michael Torres at the Temerty Faculty of Medicine has identified a novel therapeutic target for Alzheimer's disease, marking one of the most significant advances in neurodegenerative disease research in recent years. The findings, published in the journal Nature Neuroscience, reveal a previously unknown molecular pathway that plays a critical role in the accumulation of toxic protein aggregates in the brain.
The discovery centres on a protein called TREM2-L, a variant of the well-known TREM2 receptor found on microglial cells. Dr. Torres and his team demonstrated that TREM2-L acts as a master regulator of the brain's immune response to amyloid-beta plaques, the hallmark deposits associated with Alzheimer's disease. By modulating the activity of this protein in preclinical models, the researchers were able to reduce plaque burden by up to 60 percent and significantly improve cognitive function in affected subjects.
"This is the result of nearly a decade of collaborative work across multiple departments at the University of Toronto," said Dr. Torres, who holds the Canada Research Chair in Neurodegeneration. "What makes this target particularly exciting is that it appears to be druggable. We are already in discussions with pharmaceutical partners to develop small-molecule therapies that could enter clinical trials within the next two to three years."
The research was supported by a $4.2-million grant from the Canadian Institutes of Health Research (CIHR) and additional funding from the Weston Brain Institute. The study involved a multidisciplinary team of neuroscientists, immunologists, and computational biologists from the Temerty Faculty of Medicine, the Donnelly Centre for Cellular and Biomolecular Research, and the Krembil Research Institute at Toronto Western Hospital.
Alzheimer's disease affects approximately 750,000 Canadians, a number expected to double by 2040. Current treatments can only manage symptoms and do not address the underlying disease process. This breakthrough represents a potential paradigm shift in how the condition is treated, offering the possibility of therapies that could slow or even halt disease progression. The Temerty Faculty of Medicine continues to be at the forefront of neuroscience research, building on a legacy of discovery that stretches back over a century.
